L · 0QN1.L
Santhera Pharmaceuticals Holding AG
- Sector
- Healthcare · Medical - Pharmaceuticals
- Headquarters
- Pratteln 4133
- Website
- santhera.com
Price · as of 2024-12-31
$17.00
Market cap 212.95M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $194.70 | +1,045.34% |
| Intrinsic Value(DCF) | $6.45 | -62.06% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $177.10 | +941.81% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $34.10 | $0.00 | |||
| 2011 | $0.00 | $5,137.60 | |||
| 2012 | $0.00 | $0.00 | |||
| 2013 | $39.00 | $1,027.20 | $0.00 | $0.00 | $753.00 |
| 2014 | $985.00 | $587.74 | $16.67 | $0.00 | $0.00 |
| 2015 | $727.50 | $524.91 | $159.99 | $237.80 | $749.20 |
| 2016 | $0.00 | $0.00 | |||
| 2017 | $199.80 | $86.58 | $28,065.82 | $0.00 | $0.00 |
| 2018 | $154.14 | $61.66 | $17,000.33 | $0.00 | $0.00 |
| 2019 | $81.30 | $1,168.02 | $506,112.50 | $0.00 | $0.00 |
| 2020 | $29.90 | $16,003.77 | $0.02 | $0.00 | $3,246.30 |
| 2021 | $12.50 | $12.88 | $0.00 | $0.00 | $1,482.50 |
| 2022 | $6.80 | $78.47 | $0.00 | $0.00 | |
| 2023 | $10.30 | $488.27 | $136.12 | $29.50 | $5,979.90 |
| 2024 | $15.12 | $208.43 | $0.00 | $0.00 | $177.10 |
AI valuation
Our deep-learning model estimates Santhera Pharmaceuticals Holding AG's (0QN1.L) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $194.70
- Current price
- $17.00
- AI upside
- +1,045.34%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$6.45
-62.06% upside
Graham-Dodd
—
— upside
Graham Formula
$177.10
+941.81% upside
About Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
- CEO
- Dario Eklund
- Employees
- 78
- Beta
- -0.72
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($6.45 ÷ $17.00) − 1 = -62.06% (DCF, example).